On October 28, Imeik Technology Development Co.,Ltd. (300896) released its third-quarter report for 2026, showing that it generated operating revenue of 528 million yuan in the third quarter, down 6.62% year on year, while net profit attributable to shareholders reached 198 million yuan, down 34.92% over the same period.
Looking at a longer time frame, Imeik Technology Development Co.,Ltd. (300896) has faced performance pressure across several consecutive reporting periods.
In 2025, the company's revenue fell 18.94% year on year and net profit attributable to shareholders dropped 34.05%, marking the first annual decline in both revenue and net profit since its listing.
In the first three quarters of this year, the company recorded operating revenue of 1.744 billion yuan, down 6.48% year on year, while net profit attributable to shareholders came in at 791 million yuan, down 27.64%.
This shift is closely tied to intensifying competition in the medical aesthetics market and weakening growth of its traditional core products.
The company derives most of its revenue from solution-type injectable products led by its flagship hyaluronic acid filler and from gel-type injectable products represented by its regenerative collagen stimulator.
According to its previously disclosed half-year report, in the first half of this year, revenue from solution-type injectable products reached 591 million yuan, down 20.51% year on year, while revenue from gel-type injectable products came to 379 million yuan, down 23.08% year on year.
Together, the two product lines contributed about 970 million yuan in revenue, still accounting for nearly 80% of the company's total revenue in the first half.
At the same time, freeze-dried powder injectable products, which the company expanded into through the acquisition of South Korea's REGEN, are becoming a new source of revenue.
In the first half of this year, revenue from freeze-dried powder injectable products reached 209 million yuan, up 973.5% year on year, although that growth was also affected by a low consolidation base in the same period last year.
Against the backdrop of declining revenue from traditional products and accelerated promotion of new products, the company's expenses have risen markedly.
In the first three quarters, selling expenses reached 341 million yuan, up 47.57% year on year, forming a sharp contrast with the 6.48% decline in revenue over the same period.
With the rapid increase in selling expenses, the company's selling expense ratio in the first three quarters climbed to 19.56% from 12.39% a year earlier, an increase of about 7.16 percentage points.
The company explained that this was mainly due to the establishment of new product business divisions, which drove up labor costs, as well as higher marketing expenses for new products.
All of this has further squeezed the company's profit margins.
In fact, Imeik Technology Development Co.,Ltd. (300896) is also trying to find new growth drivers by expanding its product lineup.
Since the start of this year, a botulinum toxin type A injection product exclusively distributed by the company from South Korea's Huons BP has obtained a registration certificate and went on sale in August, while a radiofrequency skin treatment device developed by its controlling subsidiary has also secured a Class III medical device registration certificate.
In addition, the company completed a change in the scope of application for its flagship hyaluronic acid filler products, adding superficial facial dermal injection, further broadening the products' application scenarios.
It is worth noting that, alongside continued revenue pressure, the company's inventory scale has also increased. As of the end of September, inventory stood at 125 million yuan, up 33.93% from the end of last year, mainly due to an increase in finished goods.
In terms of cash flow, net cash flow from operating activities in the first three quarters was 748 million yuan, down 30.3% year on year.
As it expands from traditional hyaluronic acid products into regenerative materials, botulinum toxin and medical aesthetics devices, Imeik Technology Development Co.,Ltd. (300896) is going through an investment phase brought about by product structure adjustment.
At the industry level, the medical aesthetics market is undergoing a round of adjustment. Over the past few years, the industry relied on rapidly growing consumer demand and relatively high product entry barriers to support high gross margins for upstream companies. However, as competition intensifies, product supply increases and consumer demand becomes more rational, the industry's original growth model is facing challenges.
Even Imeik Technology Development Co.,Ltd. (300896), with its core products and relatively strong profitability, finds it hard to remain unaffected. For upstream medical aesthetics companies, finding new growth drivers is becoming a common test.
Comments